66 related articles for article (PubMed ID: 38440177)
1. Comparative effects of incretin-based therapy on doxorubicin-induced nephrotoxicity in rats: the role of SIRT1/Nrf2/NF-κB/TNF-α signaling pathways.
Botros SR; Matouk AI; Amin A; Heeba GH
Front Pharmacol; 2024; 15():1353029. PubMed ID: 38440177
[No Abstract] [Full Text] [Related]
2. α-Bisabolol Attenuates Doxorubicin Induced Renal Toxicity by Modulating NF-κB/MAPK Signaling and Caspase-Dependent Apoptosis in Rats.
Arunachalam S; Nagoor Meeran MF; Azimullah S; Jha NK; Saraswathiamma D; Subramanya S; Albawardi A; Ojha S
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142441
[TBL] [Abstract][Full Text] [Related]
3. The protective impact of berberine against doxorubicin-induced nephrotoxicity in rats.
Ibrahim Fouad G; Ahmed KA
Tissue Cell; 2021 Dec; 73():101612. PubMed ID: 34371291
[TBL] [Abstract][Full Text] [Related]
4. Isoliquiritigenin prevents Doxorubicin-induced hepatic damage in rats by upregulating and activating SIRT1.
Al-Qahtani WH; Alshammari GM; Ajarem JS; Al-Zahrani AY; Alzuwaydi A; Eid R; Yahya MA
Biomed Pharmacother; 2022 Feb; 146():112594. PubMed ID: 34968927
[TBL] [Abstract][Full Text] [Related]
5. Modulation of the Sirtuin-1 signaling pathway in doxorubicin-induced nephrotoxicity (synergistic amelioration by resveratrol and pirfenidone).
Manawy SM; Faruk EM; Hindawy RF; Hassan MM; Farrag DMG; Bashar MAE; Fouad H; Bagabir RA; Hassan DAA; Zaazaa AM; Hablas MGA; Kamal KM
Tissue Cell; 2024 Apr; 87():102330. PubMed ID: 38412579
[TBL] [Abstract][Full Text] [Related]
6. α-Bisabolol Attenuates NF-κB/MAPK Signaling Activation and ER-Stress-Mediated Apoptosis by Invoking Nrf2-Mediated Antioxidant Defense Systems against Doxorubicin-Induced Testicular Toxicity in Rats.
Arunachalam S; Nagoor Meeran MF; Azimullah S; Kumar Jha N; Saraswathiamma D; Albawardi A; Beiram R; Ojha S
Nutrients; 2022 Nov; 14(21):. PubMed ID: 36364909
[TBL] [Abstract][Full Text] [Related]
7. GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway.
Xiang J; Qin L; Zhong J; Xia N; Liang Y
Diabetes Metab Syndr Obes; 2023; 16():2433-2446. PubMed ID: 37602204
[TBL] [Abstract][Full Text] [Related]
8. Dapagliflozin protects against doxorubicin-induced nephrotoxicity associated with nitric oxide pathway-A translational study.
Chang WT; Wu CC; Liao IC; Lin YW; Chen YC; Ho CH; Lee WC; Lin YC; Chen ZC; Shih JY; Wu NC; Kan WC
Free Radic Biol Med; 2023 Nov; 208():103-111. PubMed ID: 37549754
[TBL] [Abstract][Full Text] [Related]
9. Semaglutide ameliorates obesity-induced cardiac inflammation and oxidative stress mediated via reduction of neutrophil Cxcl2, S100a8, and S100a9 expression.
Pan X; Yang L; Wang S; Liu Y; Yue L; Chen S
Mol Cell Biochem; 2024 May; 479(5):1133-1147. PubMed ID: 37318712
[TBL] [Abstract][Full Text] [Related]
10. Semaglutide, a novel glucagon-like peptide-1 agonist, amends experimental autoimmune encephalomyelitis-induced multiple sclerosis in mice: Involvement of the PI3K/Akt/GSK-3β pathway.
Sadek MA; Kandil EA; El Sayed NS; Sayed HM; Rabie MA
Int Immunopharmacol; 2023 Feb; 115():109647. PubMed ID: 36584570
[TBL] [Abstract][Full Text] [Related]
11. The role of ivabradine in doxorubicin-induced cardiotoxicity: exploring of underlying argument.
Al-Kuraishy HM; Issa HK; Al-Gareeb AI; El-Bouseary MM; Youssef A; Abdelaziz AS; Khalifa HA; Batiha GE
Inflammopharmacology; 2022 Dec; 30(6):2441-2446. PubMed ID: 36219320
[TBL] [Abstract][Full Text] [Related]
12. Pirfenidone and vitamin D mitigate renal fibrosis induced by doxorubicin in mice with Ehrlich solid tumor.
Hazem RM; Antar SA; Nafea YK; Al-Karmalawy AA; Saleh MA; El-Azab MF
Life Sci; 2022 Jan; 288():120185. PubMed ID: 34861286
[TBL] [Abstract][Full Text] [Related]
13. Reno-Protective Effect of GLP-1 Receptor Agonists in Type1 Diabetes: Dual Action on TRPC6 and NADPH Oxidases.
Youssef N; Noureldein M; Njeim R; Ghadieh HE; Harb F; Azar ST; Fares N; Eid AA
Biomedicines; 2021 Sep; 9(10):. PubMed ID: 34680477
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
